Coherus Oncology, Inc.
NASDAQ:CHRSBiotechnology
+$0.03 today
- Market cap
- $63.35M
- Beta
- 0.96
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.11
Volume 2.55M
Average 1.15M
CHRS Net Income
Bottom-line profit after all expenses, interest, and taxes.
Coherus Oncology, Inc.NASDAQ: CHRS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$37.94M, compared with -$56.57M a year earlier. Trailing-twelve-month net income was -$151.66M.
Context
- Net income amounted to 403.8% of revenue in FY2025, up 393.1 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$101.19M (+40.6%) for the fiscal year ending Dec 2026, a step up from the -697.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$37.94M-1.8% QoQ
- Last fiscal yearDec 2025
- -$170.29M-697.4% YoY
- LTMMar 2026
- -$151.66M-15.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +32.9% | +6.3% | -26.7 pp |
| 1 year | -697.4% | +40.6% | +737.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (170.29M) USD
- Year-over-year change
- -697.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (170.29M) | -697.4% |
| FY2024 | 2024-12-31 | 28.51M | +112.0% |
| FY2023 | 2023-12-31 | (237.89M) | +18.5% |
| FY2022 | 2022-12-31 | (291.75M) | -1.6% |
| FY2021 | 2021-12-31 | (287.1M) | — |
Net Income vs competitors
How CHRS compares with its peers on the latest reported figures
- CHRS's LTM Mar 2026 net income of -$151.66M is the lowest of the 11 companies compared; the peer median is -$58.79M.
- Its year-over-year change of -15.8% is the 7th highest of 11, against a peer median of +5.5%.
- Net income amounts to 323.5% of revenue for CHRS, versus a peer median of 242.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $15.33M | +292.3% | — | 20.1% | |
| LTM Mar 2026 | -$31.99M | +57.0% | — | 41.0% | |
| LTM Sep 2026 | -$35.76M | -37.8% | — | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$47.84M | +17.8% | — | 2454.6% |
| LTM Mar 2026 | -$54.28M | +11.4% | — | 187.7% | |
| LTM Mar 2026 | -$63.31M | -39.4% | — | — | |
| LTM Mar 2026 | -$77.6M | +45.6% | — | 138.9% | |
| LTM Mar 2026 | -$84.74M | -216.1% | — | 143627.1% | |
| LTM Mar 2026 | -$103.8M | -0.5% | — | 297.8% | |
| LTM Mar 2026 | -$123.33M | -55.2% | — | 356.9% | |
| LTM Mar 2026 | -$151.66M | -15.8% | — | 323.5% | |
| Peer median (excluding CHRS) | -$58.79M | +5.5% | — | 242.7% | |
Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 326.55M | 211.04M | 257.24M | 266.96M | 42.17M |
| Cost of Revenue | 57.59M | 70.08M | 158.99M | 117.55M | 17.74M |
| Gross Profit | 268.96M | 140.96M | 98.25M | 149.41M | 24.43M |
| Gross Margin | 82.4% | 66.8% | 38.2% | 56.0% | 57.9% |
| Research & Development | 363.11M | 199.36M | 109.44M | 93.34M | 104.96M |
| Selling, General & Admin | 169.71M | 198.48M | 185.62M | 150.44M | 99M |
| Operating Expenses | 532.82M | 397.84M | 301.45M | 261.07M | 203.97M |
| Depreciation & Amortization | 3.45M | 3.7M | 3.79M | 5.28M | 3.92M |
| EBITDA | (260.69M) | (255.58M) | (193.94M) | 60.94M | (170.2M) |
| EBITDA Margin | -79.8% | -121.1% | -75.4% | 22.8% | -403.6% |
| Operating Income | (263.86M) | (256.88M) | (203.2M) | (111.67M) | (179.53M) |
| Operating Margin | -80.8% | -121.7% | -79.0% | -41.8% | -425.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 22.96M | 32.47M | 40.54M | 27.16M | 9M |
| Other Income / Expenses | (23.24M) | (34.87M) | (35.07M) | 140.17M | (3.59M) |
| Income Before Tax | (287.1M) | (291.75M) | (238.27M) | 28.51M | (183.12M) |
| Pre-Tax Margin | -87.9% | -138.2% | -92.6% | 10.7% | -434.2% |
| Income Tax Expense | 0 | 0 | (380K) | 0 | 0 |
| Net Income | (287.1M) | (291.75M) | (237.89M) | 28.51M | (170.29M) |
| Net Margin | -87.9% | -138.2% | -92.5% | 10.7% | -403.8% |
| EPS (Basic) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| EPS (Diluted) | (3.81) | (3.76) | (2.53) | 0.25 | (1.45) |
| Weighted Avg Shares | 75.45M | 77.63M | 94.16M | 114.55M | 120.37M |
| Weighted Avg Shares (Diluted) | 75.45M | 77.63M | 94.16M | 114.83M | 120.37M |
Coherus Oncology, Inc.
NASDAQ:CHRS
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.